Riskpilot← Back to searchSign inGet full accessTMG Medical Oy
OYDissolvedY-tunnus 3093752-3Yrjönkatu 16-A4Medical specialists activities · NACE 8622Est. 2019— employees
Revenue 2025
EUR 163K
+6% vs 2024
EBITDA margin
12.6%
-94% vs 2024
Equity ratio
98.5%
Financial strength
Net profit 2025
EUR 22K
+554% vs 2024
| Revenue | EUR 163K | +6% |
| EBITDA | EUR 21K | -94% |
| Net profit | EUR 22K | +554% |
| Total assets | EUR 391K | -2% |
| Equity | EUR 385K | -2% |
| Employees | — | — |
Legal name
TMG Medical Oy
Y-tunnus number
3093752-3
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
17. lokakuuta 2019
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-11-30
Financial year
January – December
Company purpose
Lääkäripalvelujen tuottaminen potilaille, koulutus- ja konsultointipalvelujen tuottaminen, liikkeenjohdon konsultointi, luennointi sekä kustannustoiminta. Yhtiö voi harjoittaa lääketieteellistä tutkimustyötä. Yhtiö voi omistaa, hallita, vuokrata ja saneerata sekä välittää kiinteistöjä, liike- ja asuinhuoneistoja sekä kulkuneuvoja. Yhtiö voi harjoittaa arvopaperikauppaa.
Address
Yrjönkatu 16-A4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 379 | 333 | 207 | 154 | 163 |
| Staff expenses | −45 | −57 | −56 | 78 | −54 |
| EBITDA | 221 | 162 | 55 | 370 | 21 |
| Depreciation & amort. | −8 | −1 | −1 | 1 | −0 |
| EBIT | 213 | 161 | 54 | −20 | 20 |
| Net financials | 28 | −43 | 24 | 15 | 7 |
| Profit before tax | 241 | 119 | 78 | −3 | 25 |
| Tax | 50 | 32 | 11 | 2 | −3 |
| Net profit | 191 | 86 | 68 | −5 | 22 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 377 | 413 | 439 | 400 | 391 |
| Equity | 344 | 402 | 434 | 395 | 385 |
| Long-term debt | 1 | 1 | 0 | — | — |
| Short-term debt | 32 | 10 | 5 | 5 | 6 |
| Total debt | 33 | 10 | 5 | 5 | 6 |
EBITDA margin
12.6%
This company
15.8%
Market median
-20% vs market
20212025
Equity ratio
98.5%
This company
38.2%
Market median
+158% vs market
20212025
Return on equity
5.7%
This company
18.4%
Market median
-69% vs market
20212025
Net profit margin
13.5%
This company
8.1%
Market median
+67% vs market
20212025
Asset turnover
0.42×
This company
1.12×
Market median
-63% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2024-12-01 – 2025-11-30
- Annual report 2024Filed via PRH / YTJ · Period 2023-12-01 – 2024-11-30
- Annual report 2023Filed via PRH / YTJ · Period 2022-12-01 – 2023-11-30
- Annual report 2022Filed via PRH / YTJ · Period 2021-12-01 – 2022-11-30
- Annual report 2021Filed via PRH / YTJ · Period 2020-12-01 – 2021-11-30
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
AE Deputy Member | Deputy Member | 2019 |
TM Chief Executive Officer | Chief Executive Officer | 2019 |
JA | Audit | 2024 |
PR Deputy auditor | Deputy auditor | 2024 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TMG Medical Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anne Elice Frelander | Deputy Member | 0 companies |
| Thomas Mikael Gustafsson | Chief Executive Officer | 0 companies |
| Jose Adam Juhani Kautonen | Audit | 0 companies |
| Petteri Raine Lagus | Deputy auditor | 0 companies |